Cargando…
Overexpression of CCL-21/Secondary Lymphoid Tissue Chemokine in Human Dendritic Cells Augments Chemotactic Activities for Lymphocytes and Antigen Presenting Cells
BACKGROUND: Ex vivo generated dendritic cells (DC) genetically modified to express secondary lymphoid tissue chemokine (CCL-21/SLC) have been shown to stimulate potent antitumor responses in murine models. When injected intratumorally, CCL-21 colocalizes DC and lymphocyte effector cells at the tumor...
Autores principales: | Riedl, Karen, Baratelli, Felicita, Batra, Raj K, Yang, Seok Chul, Luo, Jie, Escuadro, Brian, Figlin, Robert, Strieter, Robert, Sharma, Sherven, Dubinett, Steven |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2003
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC270078/ https://www.ncbi.nlm.nih.gov/pubmed/14613584 http://dx.doi.org/10.1186/1476-4598-2-35 |
Ejemplares similares
-
Pre-clinical characterization of GMP grade CCL21-gene modified dendritic cells for application in a phase I trial in Non-Small Cell Lung Cancer
por: Baratelli, Felicita, et al.
Publicado: (2008) -
PD-L1 expression correlates with immune response in a Phase I trial of CCL21 gene modified dendritic cell therapy in lung cancer
por: Lee, Jay M, et al.
Publicado: (2014) -
Novel CCL21-Vault Nanocapsule Intratumoral Delivery Inhibits Lung Cancer Growth
por: Kar, Upendra K., et al.
Publicado: (2011) -
SLC/CCL21-mediated anti-tumor responses require IFNγ, MIG/CXCL9 and IP-10/CXCL10
por: Sharma, Sherven, et al.
Publicado: (2003) -
Chemokines during anaphylaxis: the importance of CCL2 and CCL2-dependent chemotactic activity for basophils
por: Vantur, Romana, et al.
Publicado: (2020)